




Searching News Database: multiple sclerosi
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 18 Nov 2022
Synaptogenix Announces $15 Million Private Placement with Existing Investors
Synaptogenix Announces $15 Million Private Placement with Existing Investors
HSMN NewsFeed - 25 Jul 2022
HotSpot Therapeutics Appoints Paul Thibodeau, Ph.D., as Chief Business Officer
HotSpot Therapeutics Appoints Paul Thibodeau, Ph.D., as Chief Business Officer
HSMN NewsFeed - 6 Jul 2022
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén
HSMN NewsFeed - 5 Jul 2022
Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer
Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer
HSMN NewsFeed - 4 Jan 2022
Abbott's Proclaim(TM) XR Spinal Cord Stimulation System Now Offers Expanded MRI Compatibility in U.S.
Abbott's Proclaim(TM) XR Spinal Cord Stimulation System Now Offers Expanded MRI Compatibility in U.S.
HSMN NewsFeed - 8 Nov 2021
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
HSMN NewsFeed - 14 May 2021
FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz(R) IND for Stroke Treatment
FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz(R) IND for Stroke Treatment
HSMN NewsFeed - 23 Nov 2020
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
HSMN NewsFeed - 10 Nov 2020
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer
HSMN NewsFeed - 24 Jun 2020
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
HSMN NewsFeed - 30 Oct 2019
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
HSMN NewsFeed - 15 Jul 2019
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
HSMN NewsFeed - 8 Jul 2019
Skyhawk Therapeutics Announces Expansion of Collaboration Agreement with Biogen
Skyhawk Therapeutics Announces Expansion of Collaboration Agreement with Biogen
HSMN NewsFeed - 21 Jun 2019
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
HSMN NewsFeed - 29 May 2019
ReWalk Robotics Receives CE Mark for ReStore(TM) Exo-Suit Stroke Rehabilitation Device
ReWalk Robotics Receives CE Mark for ReStore(TM) Exo-Suit Stroke Rehabilitation Device
HSMN NewsFeed - 13 Mar 2019
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
HSMN NewsFeed - 31 Oct 2018
Shavit Capital Completes $100 Million Investment Round for Its Fifth Fund
Shavit Capital Completes $100 Million Investment Round for Its Fifth Fund
HSMN NewsFeed - 31 Aug 2018
Rehan Verjee to Lead EMD Serono as Company Advances its Innovative Medicines Strategy in North America
Rehan Verjee to Lead EMD Serono as Company Advances its Innovative Medicines Strategy in North America
HSMN NewsFeed - 18 Jun 2018
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
HSMN NewsFeed - 16 Apr 2018
Apitope Announces Positive Results with Novel Treatment for Graves' Disease
Apitope Announces Positive Results with Novel Treatment for Graves' Disease
HSMN NewsFeed - 9 Apr 2018
RegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome
RegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome
HSMN NewsFeed - 26 Mar 2018
Bioness Receives FDA Clearance for myBioness(TM) iOS app for mobile control of the L300 Go(TM) System
Bioness Receives FDA Clearance for myBioness(TM) iOS app for mobile control of the L300 Go(TM) System
HSMN NewsFeed - 7 Mar 2018
New Blood Test to Accurately Detect Fibromyalgia Now Available from Data Science Company IQuity
New Blood Test to Accurately Detect Fibromyalgia Now Available from Data Science Company IQuity
HSMN NewsFeed - 6 Mar 2018
Wendy Sussman Joins EMD Serono as Vice President of U.S. Healthcare Government & Public Affairs
Wendy Sussman Joins EMD Serono as Vice President of U.S. Healthcare Government & Public Affairs
HSMN NewsFeed - 4 Jan 2018
Neurogastrx, Inc. Raises $45M Series A To Bring Lead GI Candidate Through Proof Of Concept
Neurogastrx, Inc. Raises $45M Series A To Bring Lead GI Candidate Through Proof Of Concept
HSMN NewsFeed - 18 Dec 2017
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
HSMN NewsFeed - 7 Dec 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
HSMN NewsFeed - 4 Dec 2017
Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada
Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada
HSMN NewsFeed - 1 Dec 2017
EMD Serono Appoints Zhen Su, M.D., MBA to Chief Medical Officer, North America
EMD Serono Appoints Zhen Su, M.D., MBA to Chief Medical Officer, North America
HSMN NewsFeed - 9 Nov 2017
NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
HSMN NewsFeed - 23 Oct 2017
EMD Serono Appoints Robert Truckenmiller to Senior Vice President of Market Access & Customer Solutions
EMD Serono Appoints Robert Truckenmiller to Senior Vice President of Market Access & Customer Solutions
HSMN NewsFeed - 20 Oct 2017
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 18 Sep 2017
Abide Therapeutics Appoints Dr. Sapna Srivastava As Chief Financial and Strategy Officer
Abide Therapeutics Appoints Dr. Sapna Srivastava As Chief Financial and Strategy Officer
HSMN NewsFeed - 31 Aug 2017
RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia
RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia
HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
HSMN NewsFeed - 13 Apr 2017
RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT(R) for Migraines in Luxembourg
RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT(R) for Migraines in Luxembourg
HSMN NewsFeed - 10 Apr 2017
Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs
Vericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs
HSMN NewsFeed - 8 Mar 2017
Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women's Rogaine(R) Foam
Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women's Rogaine(R) Foam
HSMN NewsFeed - 1 Mar 2017
Perrigo Announces FDA Final Approval For The Generic Version Of Axiron(R) Topical Solution, 30 mg/1.5 mL
Perrigo Announces FDA Final Approval For The Generic Version Of Axiron(R) Topical Solution, 30 mg/1.5 mL
HSMN NewsFeed - 17 Feb 2017
Perrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution
Perrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution
HSMN NewsFeed - 24 Jan 2017
Perrigo Announces FDA Approval Of Its First-To-File AB Rated Generic Version Of Topicort(R) Spray, 0.25%
Perrigo Announces FDA Approval Of Its First-To-File AB Rated Generic Version Of Topicort(R) Spray, 0.25%
HSMN NewsFeed - 13 Jan 2017
Merck KGaA, Darmstadt, Germany, and Palantir Launch New Healthcare Acceleration Partnership
Merck KGaA, Darmstadt, Germany, and Palantir Launch New Healthcare Acceleration Partnership
HSMN NewsFeed - 14 Nov 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
HSMN NewsFeed - 21 Jul 2016
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
HSMN NewsFeed - 28 Jun 2016
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
HSMN NewsFeed - 21 Jun 2016
Perrigo Announces FDA Clearance And Launch Of Non-GMO* Infant Formulas For The U.S. Store Brand Market
Perrigo Announces FDA Clearance And Launch Of Non-GMO* Infant Formulas For The U.S. Store Brand Market
HSMN NewsFeed - 30 May 2016
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
HSMN NewsFeed - 16 May 2016
The Medicines Company Appoints Tony Kingsley as President and Chief Operating Officer
The Medicines Company Appoints Tony Kingsley as President and Chief Operating Officer
HSMN NewsFeed - 13 May 2016
Alprolix(R) (rFIXFc) approved in the EU for the treatment of haemophilia B
Alprolix(R) (rFIXFc) approved in the EU for the treatment of haemophilia B
HSMN NewsFeed - 2 May 2016
Perrigo Announces FDA Approval and Launch of the Generic Version of BenzaClin(R) Pump Topical Gel
Perrigo Announces FDA Approval and Launch of the Generic Version of BenzaClin(R) Pump Topical Gel
HSMN NewsFeed - 27 Apr 2016
MedDay Appoints Catherine Moukheibir as Chairman of its Board of Directors
MedDay Appoints Catherine Moukheibir as Chairman of its Board of Directors
HSMN NewsFeed - 11 Apr 2016
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
HSMN NewsFeed - 6 Apr 2016
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
HSMN NewsFeed - 30 Mar 2016
Biogen Appoints Michel Vounatsos Executive Vice President, Chief Commercial Officer
Biogen Appoints Michel Vounatsos Executive Vice President, Chief Commercial Officer
HSMN NewsFeed - 7 Mar 2016
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
HSMN NewsFeed - 22 Jan 2016
U.S. FDA Approves BOTOX(R) (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
U.S. FDA Approves BOTOX(R) (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
HSMN NewsFeed - 17 Jan 2016
BENEPALI(R), the First Etanercept Biosimilar Referencing Enbrel(R), Approved in the European Union
BENEPALI(R), the First Etanercept Biosimilar Referencing Enbrel(R), Approved in the European Union
HSMN NewsFeed - 24 Nov 2015
Sobi and Biogen’s ELOCTA(R) (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A
Sobi and Biogen’s ELOCTA(R) (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A
HSMN NewsFeed - 10 Nov 2015
Perrigo Announces FDA Approval Of The AB Rated Generic Version Of KlorCon(R) Extended-Release Tablets
Perrigo Announces FDA Approval Of The AB Rated Generic Version Of KlorCon(R) Extended-Release Tablets
HSMN NewsFeed - 3 Nov 2015
Neurogastrx Appoints Baxter Phillips III as President and Chief Executive Officer
Neurogastrx Appoints Baxter Phillips III as President and Chief Executive Officer
HSMN NewsFeed - 1 Oct 2015
Synthetic Biologics Appoints Raymond Stapleton, PhD, as Senior Vice President, Manufacturing
Synthetic Biologics Appoints Raymond Stapleton, PhD, as Senior Vice President, Manufacturing
HSMN NewsFeed - 28 Sep 2015
Teva Announces Approval of COPAXONE(R) in Japan for the Prevention of Relapse of Multiple Sclerosis
Teva Announces Approval of COPAXONE(R) in Japan for the Prevention of Relapse of Multiple Sclerosis
HSMN NewsFeed - 28 Aug 2015
Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction
Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction
HSMN NewsFeed - 11 Aug 2015
Axiobionics(R) Announces the Launch of its Newest Therapy Device: TripleFlex
Axiobionics(R) Announces the Launch of its Newest Therapy Device: TripleFlex
HSMN NewsFeed - 9 Jun 2015
Opexa Hires Experienced Pharmaceutical Executive as Vice President of Business Development
Opexa Hires Experienced Pharmaceutical Executive as Vice President of Business Development
HSMN NewsFeed - 21 May 2015
Jose-Carlos Gutiérrez-Ramos, Ph.D. Joins Synlogic as Chief Executive Officer
Jose-Carlos Gutiérrez-Ramos, Ph.D. Joins Synlogic as Chief Executive Officer
HSMN NewsFeed - 18 May 2015
Vesiflo Introduces the inFlow Device and Its Companion Patient Monitoring System
Vesiflo Introduces the inFlow Device and Its Companion Patient Monitoring System
HSMN NewsFeed - 11 May 2015
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
HSMN NewsFeed - 27 Apr 2015
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
HSMN NewsFeed - 31 Mar 2015
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
HSMN NewsFeed - 4 Nov 2014
BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia(TM) in Europe
BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia(TM) in Europe
HSMN NewsFeed - 29 Sep 2014
Lumara Health(TM) to be Acquired in Two Separate Transactions for up to $1.107 Billion
Lumara Health(TM) to be Acquired in Two Separate Transactions for up to $1.107 Billion
HSMN NewsFeed - 21 Jul 2014
MicroCHIPS, Inc. appoints Cheryl R. Blanchard, Ph.D., as Chief Executive Officer
MicroCHIPS, Inc. appoints Cheryl R. Blanchard, Ph.D., as Chief Executive Officer
HSMN NewsFeed - 15 May 2014
Mylan Applauds Court's Ruling Dismissing Teva's Suit Against FDA on Copaxone(R)
Mylan Applauds Court's Ruling Dismissing Teva's Suit Against FDA on Copaxone(R)
HSMN NewsFeed - 14 May 2014
Acorda Therapeutics Appoints Andrew Hindman as Chief Business Development Officer
Acorda Therapeutics Appoints Andrew Hindman as Chief Business Development Officer
HSMN NewsFeed - 28 Apr 2014
Coherus Biosciences Appoints Michael A. Fleming as Senior Vice President, Commercial Strategy
Coherus Biosciences Appoints Michael A. Fleming as Senior Vice President, Commercial Strategy
HSMN NewsFeed - 28 Apr 2014
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
HSMN NewsFeed - 31 Mar 2014
New Global Initiative Aims to Improve Patient Outcomes in Metastatic Colorectal Cancer
New Global Initiative Aims to Improve Patient Outcomes in Metastatic Colorectal Cancer
HSMN NewsFeed - 24 Mar 2014
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
HSMN NewsFeed - 21 Mar 2014
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
HSMN NewsFeed - 30 Jan 2014
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
HSMN NewsFeed - 28 Jan 2014
Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE(R) (glatiramer acetate injection) 40mg/mL
Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE(R) (glatiramer acetate injection) 40mg/mL
HSMN NewsFeed - 30 Dec 2013
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
HSMN NewsFeed - 19 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
HSMN NewsFeed - 18 Dec 2013
Lineagen Announces $3.5 Million Series C Round and Close of Series B Financing
Lineagen Announces $3.5 Million Series C Round and Close of Series B Financing
HSMN NewsFeed - 16 Dec 2013
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
HSMN NewsFeed - 13 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
HSMN NewsFeed - 27 Nov 2013
GW Pharmaceuticals plc Announces Sativex(R) Regulatory Approval in Switzerland
GW Pharmaceuticals plc Announces Sativex(R) Regulatory Approval in Switzerland
HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
HSMN NewsFeed - 3 Oct 2013
Aubagio(R) Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study
Aubagio(R) Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study
HSMN NewsFeed - 17 Sep 2013
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
HSMN NewsFeed - 6 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
HSMN NewsFeed - 3 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
HSMN NewsFeed - 14 Aug 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
HSMN NewsFeed - 22 Jul 2013
GW Pharmaceuticals Files New Regulatory Application to Expand Sativex(R) Approval to France
GW Pharmaceuticals Files New Regulatory Application to Expand Sativex(R) Approval to France
HSMN NewsFeed - 28 Jun 2013
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
HSMN NewsFeed - 7 May 2013
Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease
Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease
HSMN NewsFeed - 1 May 2013
Ultragenyx Appoints Eric Yuen, MD as Chief Medical Officer and Senior Vice President
Ultragenyx Appoints Eric Yuen, MD as Chief Medical Officer and Senior Vice President
HSMN NewsFeed - 11 Apr 2013
BD Announces FDA 510(k) Clearance and Commercial Launch of BD UltraSafe PLUS(TM) Passive Needle Guard
BD Announces FDA 510(k) Clearance and Commercial Launch of BD UltraSafe PLUS(TM) Passive Needle Guard
HSMN NewsFeed - 28 Jan 2013
BrainStorm Cell Therapeutics Appoints Alon Natanson as Chief Executive Officer
BrainStorm Cell Therapeutics Appoints Alon Natanson as Chief Executive Officer
HSMN NewsFeed - 28 Jan 2013
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
HSMN NewsFeed - 28 Jan 2013
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
HSMN NewsFeed - 18 Dec 2012
FDA Clears IND For First Clinical Trial Protocol Developed Using Crowdsourcing
FDA Clears IND For First Clinical Trial Protocol Developed Using Crowdsourcing
HSMN NewsFeed - 10 Dec 2012
Nuron Biotech Acquires Commercial, Preventive Vaccine Meningitec(TM) from Pfizer
Nuron Biotech Acquires Commercial, Preventive Vaccine Meningitec(TM) from Pfizer
HSMN NewsFeed - 14 Nov 2012
StemGenex(TM) on the Forefront of Adult Stem Cell-Based Therapy for Alzheimer's
StemGenex(TM) on the Forefront of Adult Stem Cell-Based Therapy for Alzheimer's
HSMN NewsFeed - 10 Aug 2012
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs
HSMN NewsFeed - 23 Jun 2012
Teva Announces Favorable Court Ruling in COPAXONE(R) Patent Infringement Litigation
Teva Announces Favorable Court Ruling in COPAXONE(R) Patent Infringement Litigation
HSMN NewsFeed - 22 May 2012
EnVivo Pharmaceuticals Appoints Alfred Sandrock, M.D., Ph.D., to Board of Directors
EnVivo Pharmaceuticals Appoints Alfred Sandrock, M.D., Ph.D., to Board of Directors
HSMN NewsFeed - 14 May 2012
Bioness Announces FDA Clearance of Smaller Leg Cuff for Use with Its L300 Foot Drop System
Bioness Announces FDA Clearance of Smaller Leg Cuff for Use with Its L300 Foot Drop System
HSMN NewsFeed - 14 May 2012
Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
HSMN NewsFeed - 15 Feb 2012
Researchers Show TB4 Provides Both Neuroprotection and Neurorestoration after Traumatic Brain Injury
Researchers Show TB4 Provides Both Neuroprotection and Neurorestoration after Traumatic Brain Injury
HSMN NewsFeed - 30 Jan 2012
Biogen Idec Appoints Kenneth DiPietro Executive Vice President, Human Resources
Biogen Idec Appoints Kenneth DiPietro Executive Vice President, Human Resources
HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
HSMN NewsFeed - 5 Oct 2011
Major Diagnostic Breakthrough in Multiple Sclerosis Achieved with Advanced FONAR UPRIGHT(R) MRI
Major Diagnostic Breakthrough in Multiple Sclerosis Achieved with Advanced FONAR UPRIGHT(R) MRI
HSMN NewsFeed - 3 Oct 2011
Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
HSMN NewsFeed - 15 Sep 2011
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
HSMN NewsFeed - 16 May 2011
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
HSMN NewsFeed - 16 Feb 2011
sanofi-aventis to Acquire Genzyme for $74.00 in Cash Per Share Plus Contingent Value Right
sanofi-aventis to Acquire Genzyme for $74.00 in Cash Per Share Plus Contingent Value Right
HSMN NewsFeed - 9 Feb 2011
Circassia Acquires Worldwide Rights to Novel Psoriasis and Atopic Dermatitis Treatment From Airmid Inc
Circassia Acquires Worldwide Rights to Novel Psoriasis and Atopic Dermatitis Treatment From Airmid Inc
HSMN NewsFeed - 31 Jan 2011
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
HSMN NewsFeed - 5 Jan 2011
Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
HSMN NewsFeed - 9 Dec 2010
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
HSMN NewsFeed - 3 Nov 2010
Questcor Pharmaceuticals Launches Acthar for the Treatment of Infantile Spasms
Questcor Pharmaceuticals Launches Acthar for the Treatment of Infantile Spasms
HSMN NewsFeed - 23 Sep 2010
BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
HSMN NewsFeed - 7 Sep 2010
Court Denies Sandoz/Momenta's Summary Judgment of Invalidity in Copaxone(R) Litigation
Court Denies Sandoz/Momenta's Summary Judgment of Invalidity in Copaxone(R) Litigation
HSMN NewsFeed - 30 Aug 2010
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
HSMN NewsFeed - 7 Jul 2010
Acorda Therapeutics Announces Douglas Kargman Joins as Vice President of Drug Safety
Acorda Therapeutics Announces Douglas Kargman Joins as Vice President of Drug Safety
HSMN NewsFeed - 4 Jun 2010
Teva Announces Positive Results from a Study Assessing a New Formulation of Copaxone(R)
Teva Announces Positive Results from a Study Assessing a New Formulation of Copaxone(R)
HSMN NewsFeed - 25 Feb 2010
Copaxone(R) 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy and Safety
Copaxone(R) 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy and Safety
HSMN NewsFeed - 22 Feb 2010
Acorda Therapeutics Announces Adrian L. Rabinowicz Joins as Senior Vice President of Medical Affairs
Acorda Therapeutics Announces Adrian L. Rabinowicz Joins as Senior Vice President of Medical Affairs
HSMN NewsFeed - 22 Feb 2010
FDA Acknowledges Need for Daily Multiple Sclerosis Pill by Granting Fingolimod Priority Review Status
FDA Acknowledges Need for Daily Multiple Sclerosis Pill by Granting Fingolimod Priority Review Status
HSMN NewsFeed - 9 Feb 2010
Adeona Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President
Adeona Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President
HSMN NewsFeed - 3 Feb 2010
Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
HSMN NewsFeed - 25 Jan 2010
Acorda Therapeutics Announces Lauren Sabella Joins as Executive Vice President of Commercial Development
Acorda Therapeutics Announces Lauren Sabella Joins as Executive Vice President of Commercial Development
HSMN NewsFeed - 4 Jan 2010
Biogen Idec Announces President and Chief Executive Officer James C. Mullen to Retire
Biogen Idec Announces President and Chief Executive Officer James C. Mullen to Retire
HSMN NewsFeed - 2 Dec 2009
Seasoned Clinical Development Expert Joins Opexa to Lead Tovaxin(R) Development in Multiple Sclerosis
Seasoned Clinical Development Expert Joins Opexa to Lead Tovaxin(R) Development in Multiple Sclerosis
HSMN NewsFeed - 16 Nov 2009
Cannasat Therapeutics Announces New Chief Executive Officer: Anthony J. Giovinazzo, M.B.A., C.Dir.
Cannasat Therapeutics Announces New Chief Executive Officer: Anthony J. Giovinazzo, M.B.A., C.Dir.
HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 10 Sep 2009
COPAXONE(R) Significantly Reduced Disease Severity in Long-Term Treated Multiple Sclerosis Patients
COPAXONE(R) Significantly Reduced Disease Severity in Long-Term Treated Multiple Sclerosis Patients
HSMN NewsFeed - 10 Sep 2009
StemCells, Inc. to Initiate First Ever Neural Stem Cell Trial in Myelination Disorder
StemCells, Inc. to Initiate First Ever Neural Stem Cell Trial in Myelination Disorder
HSMN NewsFeed - 8 Jul 2009
GTC Biotherapeutics in-Licenses Recombinant Human Alpha-Fetoprotein from Merrimack Pharmaceuticals
GTC Biotherapeutics in-Licenses Recombinant Human Alpha-Fetoprotein from Merrimack Pharmaceuticals
HSMN NewsFeed - 16 Jun 2009
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
HSMN NewsFeed - 9 Jun 2009
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
HSMN NewsFeed - 28 Apr 2009
Long-Term Study with COPAXONE Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
Long-Term Study with COPAXONE Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
HSMN NewsFeed - 24 Feb 2009
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
HSMN NewsFeed - 23 Feb 2009
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
HSMN NewsFeed - 15 Jan 2009
Peptimmune Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis
Peptimmune Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis
HSMN NewsFeed - 18 Dec 2008
StemCells, Inc. Receives FDA Approval To Initiate Clinical Trial Of HuCNS-SC® Cells In A Myelin Disease
StemCells, Inc. Receives FDA Approval To Initiate Clinical Trial Of HuCNS-SC® Cells In A Myelin Disease
HSMN NewsFeed - 8 Oct 2008
Calistoga Pharmaceuticals Appoints Carol G. Gallagher, Pharm. D., Chief Executive Officer
Calistoga Pharmaceuticals Appoints Carol G. Gallagher, Pharm. D., Chief Executive Officer
HSMN NewsFeed - 18 Sep 2008
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
HSMN NewsFeed - 18 Sep 2008
Longest Prospective Study in MS Confirmed Robust Clinical Benefits and Safety of COPAXONE(R)
Longest Prospective Study in MS Confirmed Robust Clinical Benefits and Safety of COPAXONE(R)
HSMN NewsFeed - 8 Sep 2008
MediciNova to Present At Merriman Curhan Ford's 5th Annual Investor Summit 2008
MediciNova to Present At Merriman Curhan Ford's 5th Annual Investor Summit 2008
HSMN NewsFeed - 5 Sep 2008
Questcor Strengthens Management Team's Manufacturing and Commercial Operations Capabilities
Questcor Strengthens Management Team's Manufacturing and Commercial Operations Capabilities
HSMN NewsFeed - 5 Sep 2008
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
HSMN NewsFeed - 4 Sep 2008
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
HSMN NewsFeed - 20 Aug 2008
Biovail Appoints Dr. Neil M. Sussman Vice-President, Neurologic & Psychiatric Development
Biovail Appoints Dr. Neil M. Sussman Vice-President, Neurologic & Psychiatric Development
HSMN NewsFeed - 5 Aug 2008
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
HSMN NewsFeed - 23 Jul 2008
Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
HSMN NewsFeed - 22 Jul 2008
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
HSMN NewsFeed - 16 Jul 2008
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
HSMN NewsFeed - 8 Jul 2008
Pipex Pharmaceuticals Appoints Co-Founder and Vice Chairman Nicholas Stergis as Chief Executive Officer
Pipex Pharmaceuticals Appoints Co-Founder and Vice Chairman Nicholas Stergis as Chief Executive Officer
HSMN NewsFeed - 18 Jun 2008
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
HSMN NewsFeed - 10 Jun 2008
Merck Serono Strengthens its Prescription Medicines Portfolio in Latin America
Merck Serono Strengthens its Prescription Medicines Portfolio in Latin America
HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
HSMN NewsFeed - 4 Jun 2008
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers
HSMN NewsFeed - 30 Apr 2008
Teva Announces Global In-Market First Quarter Sales of Copaxone(R) Increased 35% to $542 Million
Teva Announces Global In-Market First Quarter Sales of Copaxone(R) Increased 35% to $542 Million
HSMN NewsFeed - 23 Apr 2008
Stem Cell Therapeutics Corp. Receives "May Proceed" From FDA for Its Phase IIb Clinical Stroke Trial and IND
Stem Cell Therapeutics Corp. Receives "May Proceed" From FDA for Its Phase IIb Clinical Stroke Trial and IND
HSMN NewsFeed - 17 Apr 2008
Biogen Idec Announces Slate of Directors for Annual Meeting of Shareholders
Biogen Idec Announces Slate of Directors for Annual Meeting of Shareholders
HSMN NewsFeed - 16 Apr 2008
Chemokine Therapeutics Announces New President And Chief Executive Officer
Chemokine Therapeutics Announces New President And Chief Executive Officer
HSMN NewsFeed - 16 Apr 2008
Merck Announces Planned Investment of $50 Million in Research Center in the US
Merck Announces Planned Investment of $50 Million in Research Center in the US
HSMN NewsFeed - 3 Apr 2008
Acorda Therapeutics Names John Librie Senior Vice President, Sales and Marketing
Acorda Therapeutics Names John Librie Senior Vice President, Sales and Marketing
HSMN NewsFeed - 24 Mar 2008
Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage
Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage
HSMN NewsFeed - 17 Mar 2008
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
HSMN NewsFeed - 13 Mar 2008
Teva Provides Update on Glatiramer Acetate 40mg for Amyotrophic Lateral Sclerosis (ALS)
Teva Provides Update on Glatiramer Acetate 40mg for Amyotrophic Lateral Sclerosis (ALS)
HSMN NewsFeed - 1 Feb 2008
MediciNova's MN-166 Reduces Persistent Black Hole Formation in Multiple Sclerosis Patients
MediciNova's MN-166 Reduces Persistent Black Hole Formation in Multiple Sclerosis Patients
HSMN NewsFeed - 22 Jan 2008
Samaritan Hires Expert Marketing Specialist to Build Up Southeast Europe Sales
Samaritan Hires Expert Marketing Specialist to Build Up Southeast Europe Sales
Additional items found! 415

Members Archive contains
415 additional stories matching:
multiple sclerosi
(Password required)
multiple sclerosi
(Password required)